Key result
Clinical prediction scores identified patients who would develop stroke-associated pneumonia, but adding five blood biomarkers provided limited added value.
Why the study?
Several clinical scoring systems and biomarkers have been proposed to predict stroke-associated pneumonia, but external and competitive validation alongside selected biomarkers was needed.
Does the addition of selected blood biomarkers improve the performance of clinical scores in predicting stroke-associated pneumonia in acute stroke patients?
Observational (n=683)
Yes
Does the addition of selected blood biomarkers improve the performance of clinical scores in predicting stroke-associated pneumonia in acute stroke patients?
Clinical scores can predict stroke-associated pneumonia with fair to strong capability, but the addition of selected blood biomarkers provides limited added predictive value that does not currently warrant their routine use.
Answers are grounded in this paper and cite their sources.
SAP scores discriminate SAP fairly to strongly; biomarkers add limited value, leaving routine integration open for prospective trials.
BACKGROUND AND PURPOSE: Several clinical scoring systems as well as biomarkers have been proposed to predict stroke-associated pneumonia (SAP). We aimed to externally and competitively validate SAP scores and hypothesized that 5 selected biomarkers would improve performance of these scores. METHODS: We pooled the clinical data of 2 acute stroke studies with identical data assessment: STRAWINSKI and PREDICT. Biomarkers (ultrasensitive procalcitonin; mid-regional proadrenomedullin; mid-regional proatrionatriuretic peptide; ultrasensitive copeptin; C-terminal proendothelin) were measured from hospital admission serum samples. A literature search was performed to identify SAP prediction scores. We then calculated multivariate regression models with the individual scores and the biomarkers. Areas under receiver operating characteristic curves were used to compare discrimination of these scores and models. RESULTS: The combined cohort consisted of 683 cases, of which 573 had available backup samples to perform the biomarker analysis. Literature search identified 9 SAP prediction scores. Our data set enabled us to calculate 5 of these scores. The scores had area under receiver operating characteristic curve of 0.543 to 0.651 for physician determined SAP, 0.574 to 0.685 for probable and 0.689 to 0.811 for definite SAP according to Pneumonia in Stroke Consensus group criteria. Multivariate models of the scores with biomarkers improved virtually all predictions, but mostly in the range of an area under receiver operating characteristic curve delta of 0.05. CONCLUSIONS: All SAP prediction scores identified patients who would develop SAP with fair to strong capabilities, with better discrimination when stricter criteria for SAP diagnosis were applied. The selected biomarkers provided only limited added predictive value, currently not warranting addition of these markers to prediction models. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01264549 and NCT01079728.
No takes yet. Share an insight, caveat, or question.
Hotter et al. (2020) conducted an observational in Stroke-associated pneumonia (n=683). 5 selected blood biomarkers (ultrasensitive procalcitonin, MR-proADM, MR-proANP, ultrasensitive copeptin, CT-proET-1) vs. Clinical SAP prediction scores alone was evaluated on Stroke-associated pneumonia (SAP) prediction (AUC delta of 0.05). Clinical prediction scores identified patients who would develop stroke-associated pneumonia, but adding five blood biomarkers provided limited added value.
Synapse has enriched 10 related papers. Consider them for comparative context: